Copyright © Inderes 2011 - present. All rights reserved.

Faron Pharmaceuticals

0.55 EUR

-9.54 %

5,615 following
Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

-9.54 %
-72.64 %
-73.56 %
-74.65 %
-76.84 %
-72.97 %
-85.70 %
-87.36 %
-84.20 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
65.71M EUR
Turnover
1.2M EUR
P/E (adj.) (25e)
-3.63
EV/EBIT (adj.) (25e)
-4.25
P/B (25e)
-10.99
EV/S (25e)
24,006.64
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
1.50 EUR
Updated
2026-02-09
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-02-10

Latest extensive report

Released: 2022-08-23

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
2/3
2026

Extraordinary general meeting '26

4/3
2026

Annual report '25

30/3
2026

General meeting '26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
My father used to say about “what ifs” that if your aunt were your uncle, she’d have… She isn’t, however—at least not yet—so if a shareholder hasn’t sold their shares, they still have the exact same stake in Faron and its future returns as they did before the announcement of the ...
4 hours ago
by Vino Pino
39
You can make a model like that look however you want. But I’ve used very generous assumptions just as a basis for discussion. My own % assumptions for phase success rates are lower. Above, there was talk about giving away shares for cheap, but this doesn’t look dirt cheap by any ...
1 hour ago
by Clark kent
14
It’s starting to get restless again. Let’s refine this model in light of current knowledge. Let’s set some quite GENEROUS assumptions for now. HR MDS patients USA+EU 10,000/yr. Pricing 100k / yr (CR-label, no premium pricing for life extension) Median time on treatment 12 months ...
3 hours ago
by Clark kent
13
Hopium is certainly not forbidden, but the reality is that no guarantor will be found for the offering at a price higher than 50 cents, at least. The current large owners know they can get their share at that price if they want, and an outsider won’t pay more. The Jalkasens’ role...
4 hours ago
4
Quite a bit of panic in the air. There’s some good commentary on the UK forum, but slightly less so on the Finnish one. Has Timppa sold? Likely a large portion. You can’t expect him to pull nearly 10 million out of his back pocket. Taking the tax benefits home and buying shares back...
4 hours ago
by MyrtsiZzz
4
I don’t know what there would be to be spooked about; were there any other possibilities besides Timo (whose holdings as an individual vs. on Faron’s shareholder list aren’t a one-to-one match because not all the shares he owns are in his individual name). I haven’t checked the matter...
4 hours ago
by Ville Kuoksa
3
Indeed – every share has an owner. What worries me is the value of information. In January and February, the first wave was dumped on retail investors. Now, in the second wave, panic is being stirred up, whether for a reason or not – and uncertain and desperate retail investors are...
4 hours ago
by Jummijammi2
2
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.